Literature DB >> 17236770

A congenital myopathy with diaphragmatic weakness not linked to the SMARD1 locus.

L Hartley1, M Kinali, R Knight, E Mercuri, C Hubner, E Bertini, A Y Manzur, C Jimenez-Mallebrera, C A Sewry, F Muntoni.   

Abstract

Severe diaphragmatic weakness in infancy is rare. Common causes include structural myopathies, neuromuscular transmission defects, or anterior horn cell dysfunction (spinal muscular atrophy with respiratory distress, SMARD1). We describe a form of infantile diaphragmatic weakness without mutations in the SMARD1 gene, in which pathological and clinical features differ from known conditions, and investigations suggest a myopathy. We identified seven cases in four families. All presented soon after birth with feeding and breathing difficulties, marked head lag, facial weakness, and preserved antigravity movements in the limbs, with arms weaker than legs. All had paradoxical breathing and paralysis of at least one hemi-diaphragm. All required gastrostomy feeding, and all became ventilator-dependent. Investigations included myopathic EMG, muscle biopsy showing myopathic changes, normal electrophysiology and no mutations in SMN1 or IGHMBP2. These seven infants are affected by a myopathic condition clinically resembling SMARD1. However, its pathogenesis appears to be a myopathy affecting predominantly the diaphragm.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17236770     DOI: 10.1016/j.nmd.2006.11.002

Source DB:  PubMed          Journal:  Neuromuscul Disord        ISSN: 0960-8966            Impact factor:   4.296


  11 in total

1.  Selective serotonin reuptake inhibitors ameliorate MEGF10 myopathy.

Authors:  Madhurima Saha; Skylar A Rizzo; Manashwi Ramanathan; Rylie M Hightower; Katherine E Santostefano; Naohiro Terada; Richard S Finkel; Jonathan S Berg; Nizar Chahin; Christina A Pacak; Richard E Wagner; Matthew S Alexander; Isabelle Draper; Peter B Kang
Journal:  Hum Mol Genet       Date:  2019-07-15       Impact factor: 6.150

2.  Mutations in MEGF10, a regulator of satellite cell myogenesis, cause early onset myopathy, areflexia, respiratory distress and dysphagia (EMARDD).

Authors:  Clare V Logan; Barbara Lucke; Caroline Pottinger; Zakia A Abdelhamed; David A Parry; Katarzyna Szymanska; Christine P Diggle; Anne van Riesen; Joanne E Morgan; Grace Markham; Ian Ellis; Adnan Y Manzur; Alexander F Markham; Mike Shires; Tim Helliwell; Mariacristina Scoto; Christoph Hübner; David T Bonthron; Graham R Taylor; Eamonn Sheridan; Francesco Muntoni; Ian M Carr; Markus Schuelke; Colin A Johnson
Journal:  Nat Genet       Date:  2011-11-20       Impact factor: 38.330

3.  Silencing of drpr leads to muscle and brain degeneration in adult Drosophila.

Authors:  Isabelle Draper; Lane J Mahoney; Satomi Mitsuhashi; Christina A Pacak; Robert N Salomon; Peter B Kang
Journal:  Am J Pathol       Date:  2014-08-08       Impact factor: 4.307

4.  Consequences of MEGF10 deficiency on myoblast function and Notch1 interactions.

Authors:  Madhurima Saha; Satomi Mitsuhashi; Michael D Jones; Kelsey Manko; Hemakumar M Reddy; Christine C Bruels; Kyung-Ah Cho; Christina A Pacak; Isabelle Draper; Peter B Kang
Journal:  Hum Mol Genet       Date:  2017-08-01       Impact factor: 6.150

5.  Cysteine mutations cause defective tyrosine phosphorylation in MEGF10 myopathy.

Authors:  Satomi Mitsuhashi; Hiroaki Mitsuhashi; Matthew S Alexander; Hiroyuki Sugimoto; Peter B Kang
Journal:  FEBS Lett       Date:  2013-08-15       Impact factor: 4.124

6.  Novel SNP array analysis and exome sequencing detect a homozygous exon 7 deletion of MEGF10 causing early onset myopathy, areflexia, respiratory distress and dysphagia (EMARDD).

Authors:  Tyler Mark Pierson; Thomas Markello; John Accardi; Lynne Wolfe; David Adams; Murat Sincan; Noor M Tarazi; Karin Fuentes Fajardo; Praveen F Cherukuri; Ilda Bajraktari; Katy G Meilleur; Sandra Donkervoort; Mina Jain; Ying Hu; Tanya J Lehky; Pedro Cruz; James C Mullikin; Carsten Bonnemann; William A Gahl; Cornelius F Boerkoel; Cynthia J Tifft
Journal:  Neuromuscul Disord       Date:  2013-03-01       Impact factor: 4.296

7.  Truncating and missense mutations in IGHMBP2 cause Charcot-Marie Tooth disease type 2.

Authors:  Ellen Cottenie; Andrzej Kochanski; Albena Jordanova; Boglarka Bansagi; Magdalena Zimon; Alejandro Horga; Zane Jaunmuktane; Paola Saveri; Vedrana Milic Rasic; Jonathan Baets; Marina Bartsakoulia; Rafal Ploski; Pawel Teterycz; Milos Nikolic; Ros Quinlivan; Matilde Laura; Mary G Sweeney; Franco Taroni; Michael P Lunn; Isabella Moroni; Michael Gonzalez; Michael G Hanna; Conceicao Bettencourt; Elodie Chabrol; Andre Franke; Katja von Au; Markus Schilhabel; Dagmara Kabzińska; Irena Hausmanowa-Petrusewicz; Sebastian Brandner; Siew Choo Lim; Haiwei Song; Byung-Ok Choi; Rita Horvath; Ki-Wha Chung; Stephan Zuchner; Davide Pareyson; Matthew Harms; Mary M Reilly; Henry Houlden
Journal:  Am J Hum Genet       Date:  2014-10-30       Impact factor: 11.025

8.  Mutations in the satellite cell gene MEGF10 cause a recessive congenital myopathy with minicores.

Authors:  Steven E Boyden; Lane J Mahoney; Genri Kawahara; Jennifer A Myers; Satomi Mitsuhashi; Elicia A Estrella; Anna R Duncan; Friederike Dey; Elizabeth T DeChene; Jessica M Blasko-Goehringer; Carsten G Bönnemann; Basil T Darras; Jerry R Mendell; Hart G W Lidov; Ichizo Nishino; Alan H Beggs; Louis M Kunkel; Peter B Kang
Journal:  Neurogenetics       Date:  2012-02-28       Impact factor: 2.660

9.  Novel caries loci in children and adults implicated by genome-wide analysis of families.

Authors:  Manika Govil; Nandita Mukhopadhyay; Daniel E Weeks; Eleanor Feingold; John R Shaffer; Steven M Levy; Alexandre R Vieira; Rebecca L Slayton; Daniel W McNeil; Robert J Weyant; Richard J Crout; Mary L Marazita
Journal:  BMC Oral Health       Date:  2018-06-01       Impact factor: 2.757

10.  Megf10 deficiency impairs skeletal muscle stem cell migration and muscle regeneration.

Authors:  Chengcheng Li; Dorianmarie Vargas-Franco; Madhurima Saha; Rachel M Davis; Kelsey A Manko; Isabelle Draper; Christina A Pacak; Peter B Kang
Journal:  FEBS Open Bio       Date:  2020-11-26       Impact factor: 2.792

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.